Virinchi has allotted 74,00,000 convertible equity warrants at an issue price of Rs 28 (face value of Rs 10 and premium of Rs 18) per share on preferential basis to promoter group entity, Vivo Bio Tech on 09 January 2026. Powered by Capital Market - Live News

Net loss of Virinchi reported to Rs 13.60 crore in the quarter ended September 2025 as against net profit of Rs 0.23 crore during the previous quarter ended September 2024. Sales declined 16.83% to Rs 61.77 crore in the quarter ended September 2025 as against Rs 74.27 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales61.7774.27 -17 OPM %17.1132.35 - PBDT2.5914.26 -82 PBT-11.581.61 PL NP-13.600.23 PL Powered by Capital Market - Live News

Net profit of Virinchi rose 36.40% to Rs 7.57 crore in the quarter ended September 2025 as against Rs 5.55 crore during the previous quarter ended September 2024. Sales rose 20.88% to Rs 40.47 crore in the quarter ended September 2025 as against Rs 33.48 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales40.4733.48 21 OPM %24.8824.10 - PBDT12.188.57 42 PBT9.605.77 66 NP7.575.55 36 Powered by Capital Market - Live News

Virinchi will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live News

Virinchi announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 15 November 2025.Powered by Capital Market - Live News